assay, this did not show an improvement in sensitivity (data not shown) but antibody costs were 2.2-fold higher than the threecolour assay. For high-throughput centres like the HMDS laboratory where over 2000 such assays are performed per year this equates to a potential saving of d70 000 (h100 000 or $140 000) per year in reagent costs when using the single-tube six-colour assay compared to multi-tube four-colour analysis. In addition to the major reduction in cost compared to three-/fourcolour analysis, acquisition time was reduced and gating was more straightforward and reproducible as all the relevant markers were present in the same test.
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. We read with interest the recent article on donor lymphocyte infusions (DLI) for 81 chronic myeloid leukemia (CML) patients, who relapsed after allogeneic hematopoetic stem cell transplantation (HSCT). 1 The authors report that response to DLI is dose-dependent and the effective cell dose is influenced by the quantity and phase of CML at relapse and degree of donorrecipient histocompatibility. The investigators analyzed the possible impact on response to DLI of several other factors including donor-recipient sex mismatch, post-DLI acute graftversus-host disease (GVHD), T-cell depletion at the time of stem cell transplantation (SCT), interval between either SCT or relapse and first DLI, patient's age at the time of DLI, and none turned out to be statistically significant. The effect of a functional spleen on DLI response was not addressed in their study.
Based on our previous experience in a splenectomized patient with CML, in whom a GVL reaction could not be obtained with escalating doses of DLI, we hypothesized the possible role of spleen in development of GVL and GVH reactions. Interestingly, splenectomy was not stressed at all in the literature among several factors that may influence DLI response.
Findings observed by other investigators supported an increased frequency of GVHD in splenectomized patients. [2] [3] [4] A significantly increased risk of post-transplant relapses in splenectomized patients with CML has been previously reported. 2 Unexpectedly, they observed a trend towards increased risk of GVHD, as well. Thus, increased relapse risk with an increased incidence of GVHD may point to a critical role of spleen in differentiating GVH and GVL reactions.
In our previous experience, a 16-year-old, splenectomized male with CML, who underwent allogeneic HSCT from matched sibling donor, failed to respond to escalating doses of DLIs in post-transplantation relapse at þ 14 months (4 Â 10 7 , 8 Â 10 7 , 1 Â 10 8 and 2 Â 10 8 CD3 þ T cells/kg, q4-8 weeks). The relapse was in chronic phase. Although grade I-II acute GVHD was observed following first DLI, no GVL reaction was noted. The remaining infusions were not associated with GVH or GVL reactions, in spite of concurrent a-interferon use. The patient underwent second transplantation and currently is in complete remission with 100% donor chimerism and negative bcr/abl transcripts at þ 28 months following the second transplant.
Upon our clinical observation of unresponsiveness to escalating doses of DLI in a splenectomized patient with CML in post-transplant relapse, we are raising the question of whether the spleen is an important organ in initiating and maintaining a GVL response, or perhaps in differentiating GVHD and GVL reactions on the basis of the previous literature 2 reporting an increased incidence of relapse and GVHD in previously splenectomized patients undergoing an allogeneic HSCT. On the other hand, the increased incidence of post-transplant relapses in splenectomized patients may reflect a more advanced pre-transplant stage of disease. Thus, a decreased response to DLI may be expected in splenectomized patients. In the absence of a splenic function, the patient might be unable to initiate a GVL response. CD4 þ T cells are involved in antileukemia response, and splenectomy may contribute to an increased relapse rates by removal of splenic CD4 þ T cells and decreased GVL reactivity, without an associated decrease in GVH reaction in which CD8 cells are suggested as effectors. 5 Studies have proposed that CD4 þ T cells can eliminate tumors through activation and recruitment of effector cells including macrophages, 6 and the removal of the spleen, a reservoir of macrophages, may further interfere with anti-tumor responses.
Based on these observations and postulations, further studies investigating the role of prior splenectomy in DLI response may be informative and the data of the study by Simula et We read with interest the recent letter to the editor by Uckan-Ç etinkaya et al. 1 concerning an article we have recently published in this journal. 2 In this report, we investigated the factors affecting the dose required to achieve remission (effective cell dose (ECD)) in patients with chronic myeloid leukemia (CML) treated with donor lymphocyte infusions (DLI) in an escalating dose regimen (EDR), concluding that the response to DLI is dose dependent and that the main factors influencing the ECD are the disease stage at relapse and the degree of donor-recipient histocompatibility. 2 Based on a previous experience in a 16-year-old, splenectomized male with CML, in whom response to DLI could not
